- Home
- SBRA vs IOVA Comparison
SBRA vs IOVA Comparison
Compare SBRA & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- IOVA
- Stock Information
- Founded
- SBRA 2010
- IOVA 2007
- Country
- SBRA United States
- IOVA United States
- Employees
- SBRA N/A
- IOVA N/A
- Industry
- SBRA Real Estate Investment Trusts
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBRA Real Estate
- IOVA Health Care
- Exchange
- SBRA Nasdaq
- IOVA Nasdaq
- Market Cap
- SBRA 4.6B
- IOVA 975.1M
- IPO Year
- SBRA N/A
- IOVA N/A
- Fundamental
- Price
- SBRA $18.86
- IOVA $2.24
- Analyst Decision
- SBRA Buy
- IOVA Buy
- Analyst Count
- SBRA 7
- IOVA 11
- Target Price
- SBRA $20.71
- IOVA $11.90
- AVG Volume (30 Days)
- SBRA 2.1M
- IOVA 9.5M
- Earning Date
- SBRA 10-30-2025
- IOVA 11-06-2025
- Dividend Yield
- SBRA 6.35%
- IOVA N/A
- EPS Growth
- SBRA 236.12
- IOVA N/A
- EPS
- SBRA 0.76
- IOVA N/A
- Revenue
- SBRA $734,008,000.00
- IOVA $241,525,000.00
- Revenue This Year
- SBRA $6.55
- IOVA $67.40
- Revenue Next Year
- SBRA $7.83
- IOVA $56.32
- P/E Ratio
- SBRA $24.88
- IOVA N/A
- Revenue Growth
- SBRA 10.21
- IOVA 636.99
- 52 Week Low
- SBRA $15.60
- IOVA $1.64
- 52 Week High
- SBRA $20.03
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- SBRA 48.15
- IOVA 44.45
- Support Level
- SBRA $18.81
- IOVA $2.19
- Resistance Level
- SBRA $19.19
- IOVA $2.38
- Average True Range (ATR)
- SBRA 0.33
- IOVA 0.14
- MACD
- SBRA -0.07
- IOVA -0.01
- Stochastic Oscillator
- SBRA 39.02
- IOVA 32.05
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.